Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy.
Department of Ophthalmology, Miguel Servet University Hospital, University of Zaragoza, Zaragoza, Spain.
Curr Med Chem. 2019;26(22):4241-4252. doi: 10.2174/0929867326666190725160621.
Glaucoma is the second leading cause of blindness in the world, affecting more than 60 million people globally. In order to reduce the progression of the disease, both medical and surgical treatments are used. Frequent side effects of both treatments include a range of modifications of the ocular surface grouped as the Ocular Surface Disease (OSD), which include Dry Eye Disease (DED). DED and other OSD negatively impact on the success of anti-glaucoma treatments and reduce the adherence to medical therapies. Tear film osmolarity (TFO) is a relatively novel test which has become a hallmark of DED. The aim of this paper was to review the association between OSD, DED and glaucoma in view of published TFO data, and to discuss future fields of research and treatments on the topic of glaucoma iatrogenic damage.
青光眼是全球第二大致盲原因，影响全球超过 6000 万人。为了减缓疾病进展，医学和手术治疗都被使用。这两种治疗方法的常见副作用包括一系列被归类为眼表面疾病（OSD）的眼表面改变，其中包括干眼（DED）。DED 和其他 OSD 会对青光眼治疗的成功产生负面影响，并降低对医学治疗的依从性。泪膜渗透压（TFO）是一种相对较新的测试，已成为 DED 的标志。本文旨在回顾基于已发表的 TFO 数据的 OSD、DED 和青光眼之间的关联，并讨论关于青光眼医源性损伤的未来研究和治疗领域。
